RA
PAHC icon

Royce & Associates’s Phibro Animal Health PAHC Stock Holding History

Royce & Associates’s Portfolio PAHC Stock Details PAHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,722
Closed -$45K – 1124
2020
Q2 		$45K Buy
1,722
+157
+10% +$3.9K ﹤0.01% 1049
2020
Q1 		$38K Sell
1,565
-292
-16% -$7.14K ﹤0.01% 1038
2019
Q4 		$46K Sell
1,857
-463
-20% -$10.7K ﹤0.01% 1051
2019
Q3 		$49K Buy
2,320
+1,210
+109% +$33.1K ﹤0.01% 1051
2019
Q2 		$35K Buy
1,110
+31
+3% +$972 ﹤0.01% 1065
2019
Q1 		$36K Buy
1,079
+311
+40% +$9.68K ﹤0.01% 1072
2018
Q4 		$25K Buy
768
+108
+16% +$4.08K ﹤0.01% 1072
2018
Q3 		$28K Buy
660
+268
+68% +$12.7K ﹤0.01% 1113
2018
Q2 		$18K Buy
392
+130
+50% +$5.76K ﹤0.01% 1142
2018
Q1 		$10K Sell
262
-66
-20% -$2.44K ﹤0.01% 1179
2017
Q4 		$11K Buy
+328
New +$11.6K ﹤0.01% 1170

Other funds holding PAHC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $7.03B AUM 11.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Royce & Associates's PAHC Position: Q3 2020 in Review

Royce & Associates sold out of Phibro Animal Health (PAHC) in Q3 2020, closing a stake of 1,722 shares — an estimated $45K sold.

Royce & Associates first reported a position in PAHC in Q4 2017 and held it in 11 quarters. The position peaked at $49K in Q3 2019. 136 funds tracked by Wall St. Rank hold PAHC as of Q3 2020.

  • Royce & Associates reported no remaining Phibro Animal Health position as of Q3 2020 after selling out during the quarter.
  • Royce & Associates sold 1,722 Phibro Animal Health shares in Q3 2020, an estimated $45K.
  • Royce & Associates first reported a position in Phibro Animal Health in Q4 2017 and held it in 11 quarters.
  • Royce & Associates's Phibro Animal Health position peaked at $49K in Q3 2019.
  • 136 funds tracked by Wall St. Rank held Phibro Animal Health as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.